
The BioHub - by Avetix
Max Brennan - Biotech HeadHunterAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 30 minutes
- Latest episode:
About this show
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape.
Subscribe now and be part of the conversation that's shaping the future of biotechnology.
Get ready for an immersive experience into the world of biotech with The BioHub.
Covers: biotechnology, drug discovery, biotech careers, AI in drug development, clinical trials, biotech leadership, computational biology, rare diseases
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The BioHub is a podcast hosted by biotech recruiter Max Brennan, who talks with leading people in biotechnology about the strategies and stories behind their work. Recent episodes cover machine learning in drug discovery, treatments for cannabis use disorder, and overcoming drug resistance in cancer.
Cosmos
Similar in subject
- The Genetics Podcast
Both cover: drug discovery, rare diseases - BiotechTV - News
Both cover: biotechnology, clinical trials - The BioCentury Show
Both cover: rare diseases, clinical trials
Similar shows
- The Biotech Startups Podcast
- The Bitter Truth About Food Podcast
- The BoldlyGo Podcast: Revolutionizing Your Journey
- The Brainy Business | Understanding the Psychology of Why People Buy | Behavioral Economics
- The Brülosophy Podcast
- The Building Science Podcast
- The Bulletproof Musician
- The chemical breakdown & Chemistry in its element
Explore more
Episodes
Episode 239 - Eran Seger - CEO & Co-Founder Protai
· 23 min
In this episode of The BioHub by Avetix, I’m joined by Eran Seger, CEO and Co-Founder of Protai. Eran shares his unique journey into biotech and the inspiration behind founding Protai, where the team is combining proteomics and AI to better understand disease biology and improve how new medicines are discovered. We discuss what makes Protai’s platform different, the realities of being a first-time founder and CEO, the challenge of bringing technology and biotech teams together, and where Eran believes AI can genuinely transform drug discovery.
Not rated yetEpisode 238 - Mandana Honu Fathom Therapeutics
· 27 min
We welcomed Mandana Honu onto the BioHub podcast
Not rated yetEpisode 237 - Marc Hedrick & Russell Bradley- Cerenome
· 30 min
In this episode of The BioHub Podcast, Ben is joined by Dr. Marc Hedrick, President & CEO of Cerenome, and Russell Bradley, President & General Manager of CNSide Diagnostics. We explore why CNS cancers remain so difficult to diagnose and treat, and how Cerenome is attempting to address both sides of that problem. Russell takes us inside CNSide®, the company’s cerebrospinal fluid-based diagnostic platform, including how it differs from traditional cytology, the importance of rare-cell characterisation, and what better diagnostic information could mean for treatment decisions. Marc then discusses REYOBIQ™, Cerenome’s targeted radiotherapeutic platform, the challenge of delivering sufficient therapeutic intensity into the CNS while managing toxicity, and the broader opportunity to connect diagnosis, treatment and longitudinal monitoring. A fascinating conversation at the intersection of diagnostics, therapeutics and precision CNS oncology.
Not rated yetEpisode 236 - Dan O’Connell - President & CEO of Acumen Pharmaceuticals
· 26 min
In this episode of The BioHub by Avetix, I’m joined by Dan O’Connell, President and CEO of Acumen Pharmaceuticals. Dan shares his journey from neuroscience investing and company creation into the CEO role, and how he has helped take Acumen from a private, preclinical biotech into a publicly traded clinical-stage company focused on Alzheimer’s disease. We discuss the origins of Acumen, what it was like taking the company public with just nine people, navigating a difficult few years for biotech, balancing financial discipline with clinical progress, and the major readout ahead later this year.
Not rated yetEpisode 235 - Paul Hastings - CEO NKarta
· 42 min
In this episode of The BioHub by Avetix, I’m joined by Paul Hastings, CEO of Nkarta. Paul has spent more than three decades in biotech, leading companies across oncology, rare disease and cell therapy, while also becoming one of the industry’s most prominent patient advocates. At Nkarta, he’s now leading the development of allogeneic NK cell therapies designed to make cell therapy safer, more scalable and more accessible. We discuss the evolution of biotech since Paul entered the industry in 1989, the future of cell therapy, the challenges of scaling access, the US clinical and regulatory environment, the importance of patient advocacy, and the mentors and lessons that have shaped his career.
Not rated yetEpsiode 234 - Lei Fang CEO Excalipoint
· 24 min
We welcomed Lei Fang the CEO of Excalipoint to the BioHub
Not rated yetEpisode 233 - Jay Fine - President R&D at Evolveimmune Therapeutics
· 35 min
Today we’re joined by Jay Fine, President of Research & Development at EvolveImmune Therapeutics. Jay has spent more than 30 years working across drug discovery and development, with a career spanning immunology, immuno-oncology, inflammatory diseases and respiratory disorders. Before joining EvolveImmune, he spent many years at Boehringer Ingelheim, where he led global research efforts in immunology and respiratory diseases, with his teams playing a key role in advancing therapies including Skyrizi and Spevigo. Earlier in his career, Jay held leadership and research positions at Roche, Schering-Plough and the National Cancer Institute, giving him experience across academia, large pharma and biotech. Today, we’ll talk about Jay’s journey through the field, the lessons he’s learned from taking medicines from discovery into development, his experience building and leading scientific teams, and what he sees as the biggest opportunities and challenges in drug development today.
Not rated yetEpisode 232 - Alan Bash - President Legend Biotech
· 23 min
Editor’s note: At the time of recording, Alan Bash was serving as Interim CEO of Legend Biotech. He has since resumed his role as President of CARVYKTI® following the appointment of Ingrid Zhang as CEO. In this episode of The BioHub by Avetix, I’m joined by Alan Bash, President of CARVYKTI® at Legend Biotech. Alan shares what drew him to Legend, what he believes has made the company such a standout success in cell therapy, and his experience stepping into the Interim CEO role during an important period of transition. We also discuss the journey behind CARVYKTI, the importance of global partnerships, the challenges of manufacturing and scaling cell therapy, and what the next chapter could look like for Legend as it builds beyond its first major commercial success.
Not rated yetEpisode 231 - Stacy Blain - CEO & Founder of Concarlo Therapeutics
· 38 min
Today we’re joined by Dr. Stacy Blain, Founder and CEO of Concarlo Therapeutics. Stacy has spent more than 30 years working in cell cycle and cancer biology, including two decades as a tenured professor and NIH-funded researcher at SUNY Downstate. She then made the transition from academia into entrepreneurship, founding Concarlo to develop new approaches to treating drug-resistant cancers. At Concarlo, Stacy and the team are focused on p27 biology and developing their LOCKTAC approach to target CDK2, CDK4 and CDK6, with an initial focus on drug-resistant breast cancer. Today, we’ll talk about Stacy’s journey from academic scientist to biotech founder, what led her to make that transition, the science behind Concarlo, and what she’s learned from building a company around her own research.
Not rated yetEpisode 230 - Nick Sireau - Chairman at Serenatis Bio
· 24 min
In this episode of The BioHub Podcast by Avetix, Ben O’Keefe sits down with Nick Sireau, Executive Chairman and Co-Founder of Serenatis Bio, to discuss the company’s mission to develop a new generation of treatments for obsessive-compulsive disorder (OCD). Nick shares the deeply personal story behind Serenatis, from his own experience living with OCD to the loss of a close friend to the condition, and how that ultimately helped shape the company’s focus. They explore why OCD remains a significantly underserved area of neuropsychiatry, what the biology of compulsivity can teach us more broadly, and Serenatis’ approach to developing novel mechanisms targeting glutamate, neuroinflammation and dopamine-related pathways. Nick also discusses the company’s lead programme, plans to enter Phase 1b development, the role neuroimaging could play in demonstrating early proof of biology, and what Serenatis is aiming to achieve over the next 18 months. A fascinating conversation on building a neuroscience company around both strong biology and a very personal mission.
Not rated yetEpisode 229 - Frederic Marrache - CEO of Bionyra
· 27 min
On this episode we feature the CEO of Bionyra, Frederic Marrache, after closing French-biotech's largest ever Series A ($165million) this summer. Bionyra are a Sofinnova-incubated I&I biotech advancing in-licensed monoclonal (TL1A & IL25) & bispecific (TL1AxIL-23p19) HLE antibodies for a range of autoimmune indications. In this conversation we discuss why, after a decade within Sanofi's I&I development organisation, Frederic viewed the Bionyra opportunity as 'the one' to scratch his biotech itch. Naturally, we then discuss the promise of their technology which led to the likes of Jeito & Sanofi's CVC to participate in their record breaking Series A. Frederic also discusses indication expansion possibilities, and an upcoming 18-24 months that promise to be milestone-rich. One to check-out for anyone interested in immunology drug-development and particularly those with an eye on company building in Europe.
Not rated yetEpisode 228 - Edward Van Wezel - Founder BGV
· 28 min
In this episode of The BioHub by Avetix, I’m joined by Edward van Wezel, Managing Partner and Co-Founder of BioGeneration Ventures. Edward shares his journey into venture capital and the story behind building BGV into one of Europe’s leading early-stage life sciences investors. We discuss how he evaluates companies at the earliest stages, what he looks for in founders and leadership teams, and the lessons behind standout investments such as Acerta Pharma. We also explore the evolution of the European biotech ecosystem, the challenges of fundraising and company creation, and what Edward believes Europe needs to do to build more globally competitive biotech companies.
Not rated yetEpisode 227 - Jo Lane - VP People at Compass Pathways
· 33 min
Today, I’m joined by Jo Lane, a senior People and HR leader currently working with COMPASS Pathways, where she plays a key role in supporting the organisation and its people as the company continues to develop and grow. Jo has built an impressive career across the life sciences and healthcare sectors, with senior HR and organisational development roles at COMPASS Pathways, Ipsen and IQVIA. Her experience spans people strategy, organisational development, talent, leadership, change and building high-performing teams across global organisations. Today, we’re going to talk about Jo’s journey through HR and into biotech, her experience supporting companies through periods of growth and transformation, and what she’s learned about building the right culture and teams along the way. We’ll also explore leadership, talent retention and how the role of HR continues to evolve within the biotech industry.
Not rated yetEpisode 226 - Tony Estrada - CEO & Co-founder Tenvie Therapeutics
· 24 min
In this episode of The BioHub by Avetix, I’m joined by Tony Estrada, Co-Founder and CEO of Tenvie Therapeutics. Tony shares his journey from Genentech and Denali Therapeutics to founding Tenvie, and why he chose to build a company focused on some of the toughest challenges in neuroscience. We discuss what it takes to launch a biotech in a difficult funding environment, why being scrappy and disciplined matters, and how Tenvie is balancing near-term clinical progress with continued investment in discovery. We also explore the future of neuroscience, the importance of mentorship, and where Tony believes AI and machine learning can genuinely improve drug discovery.
Not rated yetEpisode 225 - Kristen Stants - Chief People Officer Parabalis
· 21 min
In this episode of The BioHub by Avetix, I’m joined by Kristen Stants, Chief People Officer at Parabilis Medicines. Recorded shortly after Parabilis completed its record-breaking IPO, Kristen shares what that milestone means for the company and how the people strategy changes when a biotech suddenly enters a new phase of rapid growth. We also discuss how to protect culture while scaling, the qualities that help people thrive in biotech, what strong leadership looks like in a volatile industry, and Kristen’s advice for the next generation looking to build a career in HR.
Not rated yetEpisode 224 - Wyatt McDonnell - CEO of Infinimmune
· 35 min
On this episode of the podcast we feature CEO & Co-Founder of Infinimmune, Wyatt McDonnell, to discuss a hugely impressive & milestone-rich journey since founding in 2022. Infinimmune was founded on the belief that human disease is best treated with truly human therapeutics. Their discovery platform, developed by Wyatt and his five former 10X Genomics colleagues, has already been tapped by Merck in a partnering deal potentially worth $800million plus. The first two of their immune system-derived antibodies are heading toward the clinic in Atopic Dermatitis, and the Series A round to fund those trials attracted interest from Regeneron's venture arm. On a more personal note, this episode also offers great insight into Wyatt's own journey into biotech and the entrepreneurial traits that lead to him going 'all-in' on Infinimmune. He also gives his advice for anyone in a similar position looking to go on that journey.
Not rated yetEpisode 223 - Brent Richards -Founder & CEO | 5 Prime Sciences
· 15 min
In this episode of The BioHub Podcast, Amber is joined by Dr. Brent Richards, Founder and CEO of 5 Prime Sciences, a company helping biotech, pharma and investors use human genetics to make better drug development decisions. Brent shares his background in clinical medicine and human genetics, the story behind 5 Prime Sciences, and how genetic evidence can help identify and validate drug targets. We explore the challenges of translating complex data into actionable insights, why understanding causal biology matters, and the opportunity to bring greater confidence to early drug discovery.
Not rated yetEpisode 222 - Frederic Sweeney - CEO VedaBio
· 35 min
Today I’m joined by Frédéric Sweeney, President and CEO of VedaBio. Fred has spent his career at the intersection of healthcare, diagnostics, venture capital and company building. He’s also been involved with a number of companies as an investor, board member and advisor. Today, Fred is leading VedaBio, which is developing a new approach to molecular diagnostics using CRISPR. The company’s technology is designed to deliver highly accurate molecular detection much faster and closer to the point of care, with the goal of making sophisticated molecular testing much more accessible. I’m really looking forward to hearing about Fred’s journey through the industry, what he’s learned from working across startups, large diagnostics companies and venture capital, and then diving into what VedaBio is building and where he sees the future of molecular diagnostics going.
Not rated yetEpisode 221 - Steve Tregay - Managing General Partner Mission Biocapital
· 28 min
In this episode of The BioHub by Avetix, I’m joined by Steve Tregay, Managing General Partner at Mission BioCapital. Steve shares his journey across research, pharma, biotech company building and venture capital, including the story behind founding FORMA Therapeutics and the lessons that experience taught him about creating successful biotech companies. We also discuss how Mission BioCapital approaches early-stage company creation, what Steve looks for in founders and new opportunities, the role big pharma plays in the biotech ecosystem, and what he believes separates the companies that ultimately succeed from those that don’t.
Not rated yetEpisode 220 - Hans Schambye - CEO BOOST Pharma
· 25 min
In this episode of The BioHub by Avetix, I’m joined by Hans Schambye, CEO of BOOST Pharma. Hans shares what drew him to BOOST and the opportunity to develop what could become the first disease-modifying treatment for osteogenesis imperfecta. We discuss the challenge of taking a novel cell therapy from early clinical success towards Phase III, and what it takes to build the company around that journey. We also explore the lessons Hans has learned from leading and scaling multiple biotech companies, how the CEO role changes through different stages of growth, and where he sees the cell and gene therapy landscape heading next.
Not rated yet